

Corporate News

August 25, 2016

MagForce AG to attend four upcoming international conferences in September

Berlin, Germany and Nevada, USA, August 25, 2016 - MagForce AG (Frankfurt, Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today that the Company will participate in four upcoming scientific and investor conferences in September:

- **EANS 2016 Congress**
Date: September 4-8, 2016
Location: Athens, Greece
Booth: No. 17, level 0
Presentation: Dr. med. Mohammed Jaber, Clinic and Policlinic for Neurosurgery, University Hospital Münster, "NanoPaste: Thermotherapy via nanoparticles directly instilled onto glioma resection cavity walls - technique and feasibility", Tuesday, 6 September, 2016, 17:00-19:00 EEST
- **Goldman Sachs European Medtech and Healthcare Services Conference**
Date: September 7-8, 2016
Location: London, UK
Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 8, 2016; 15:15 BST
- **36th ESSO Congress**
Date: September 14-16, 2016
Location: Krakow, Poland
Booth: No. 3
- **Berenberg & Goldman Sachs Fifth German Corporate Conference 2016**
Date: September 19-21, 2016
Location: Munich, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Wednesday, September 21, 2016; 11:45 CET

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage

Corporate News

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm™, NanoPlan, and NanoActivator® are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: [video \(You Tube\)](#)

Stay informed and subscribe to our [mailing list](#)

For meeting arrangements or any further questions, please contact us at:

Patient Advocacy

Dr. Katarzyna Zarychta

+49 30 95 477 95-66

k.zarychta@magforce.com

Medical Liaison

Dr. Ulrike Boettcher

+49 89 95 477 95-64

u.boettcher@magforce.com

Media & Investors

Barbara v. Frankenberg

+49 30 30 83 80-77

b.frankenberg@magforce.com

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Corporate News

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768